Professor Saoirse O’Sullivan, vice president of translational sciences at Artelo Biosciences Inc., (NASDAQ:ARTL) presented new research results entitled, “Discovery and preclinical evaluation of a novel inhibitor of FABP5, ART26.12, effective in chemotherapy-induced pain,” during the opening oral session of the International Cannabinoid Research Society (ICRS) symposium.
“Our pre-clinical research showed that chronic, oral treatment with ART26.12, our lead FABP5 inhibitor, was effective at both preventing and treating both oxaliplatin and paclitaxel-induced pain sensitivity without any sedating effects,” stated O’Sullivan. “In the prevention studies, ART26.12 also minimized the acute weight loss caused by oxaliplatin. These results support further development of ART26.12 in neuropathy associated with chemotherapy and other neuropathies,” continued O’Sullivan.
